Sign in
Taking people in United StatesNo phase

Tests urine samples for signs of bladder and kidney cancer

Checks DNA and proteins in urine to help detect urothelial cancer in adults.

Key facts

Who runs it
Lahey Clinic
Where
Burlington, United StatesSee the site
Trial code
Registry title
Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
Status
Recruiting
People taking part
500 people, planned
Started
Sept 2002
Expected to end
Nov 2028
Type of study
Observational, 2 groups
Record updated
8 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who are scheduled for bladder or kidney cancer surgery or a bladder exam, and for adults with no known bladder cancer who give one urine sample as a control group.

Age
Older than 18 years
Sex
All sexes
Disease stage
Newly diagnosed bladder cancer, or bladder cancer that has come back and is being followed up. A control group has no known bladder cancer.

Main reasons for not taking part

  • Younger than 18 years of age

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Patients scheduled to have a nephroureterectomy, cystectomy, cytoscopy (newly diagnosed bladder cancer and those with recurrent disease in follow up)
  • Control Group: No known evidence of bladder cancer-one urine sample
  • > than 18 years of age

Who cannot take part

  • < than 18 years of age

Where in United States

  • Lahey Clinic, IncBurlington, United StatesContact: Arthur Mourtzinos, M.D. (sub-investigator)Taking people

About the trial

What the trial wants to find out

The purpose of this study is to determine if analysis of DNA and protein material found in urine will be useful in the detection of urothelial cancer of the bladder and kidney. This analysis may be helpful to determine if how a particular cancer will act regarding remission and recurrence

The 2 groups in the trial

  • 1

    Bladder Cancer Group: Patients scheduled to have a cystectomy or cystoscopy of their bladder with possible removal or biopsy of bladder tumor or tissue. Two urine samples collected at the time of the scheduled procedure: One sample collected through voiding. The other sample collected from atheterized urine in the operating room. Additional urine samples may be collected at each follow up visit over two years. These samples will be obtained via voiding, standard urine sample collection.

  • 2

    Control Group: Patients with no known evidence of bladder cancer. One urine sample will be collected through voiding, as with standard urine sample collection at the time of clinic visit.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer of the Bladder and Kidney
Plain-language title
Tests urine samples for signs of bladder and kidney cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
8 December 2025